Literature DB >> 28363663

Enzymatic debridement of deeply burned faces: Healing and early scarring based on tissue preservation compared to traditional surgical debridement.

Alexandra Schulz1, Paul Christian Fuchs2, Irene Rothermundt2, Alexandra Hoffmann2, Lior Rosenberg3, Yaron Shoham3, Henrik Oberländer2, Jennifer Schiefer2.   

Abstract

INTRODUCTION: Facial burns occur frequently and depending on the injured skin layers often heal with scars which may cause permanent functional and cosmetic sequelae. Preservation of the sensitive facial skin layers, especially of the dermis is essential for scarless epithelialisation. Enzymatic debridement of deep thermal burns has already been shown to assist with preserving viable dermis. However, up to date, there are no published reports on wound healing and in the long term aesthetic outcome after enzymatic debridement of facial burns.
METHODS: Therefore we performed a-single centre clinical trial that included 26 subjects aged 18-78 years with facial burns clinically evaluated as deep dermal or deeper. Burns were treated either with enzymatic debridement or excisional surgical debridement. Then we compared both groups regarding debridement selectivity, wound closure and scar quality after more than 12 months.
RESULTS: Enzymatic debridement significantly reduced time to complete wound closure after admission (19.85 days versus 42.23 days, p=0.002), and after enzymatic eschar removal (18.92 days versus 35.62 days, p=0.042). The number of procedures to complete debridement were significantly lower in the enzymatic debridement group (1.00 versus 1.77, p=0.003). 77% of facial burns that had been debrided enzymatically were found to be more superficially burned than initially estimated. Wounds undergoing autografting of any size were significantly reduced by enzymatic debridement (15% versus 77%, p=0.002). Scar quality after enzymatic debridement was superior compared to surgical debridement after 12 months regarding pigmentation (p=0.016), thickness (p=0.16), relief (p=0.10), pliability (p=0.01), surface area (p=0.004), stiffness (p=0.023), thickness (0.011) and scar irregularity (p=0.011). Regarding erythema and melanin, viscoelasticity and pliability, trans-epidermal water loss or laser tissue oxygen saturation, haemoglobin level and microcirculation we found no significant differences for treated and untreated skin in the EDNX group.
CONCLUSION: In our current study we found Bromelain based enzymatic debridement better in some aspects of tissue preservation in deep dermal facial burn.
Copyright © 2017 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Keywords:  Bromelain; Burn eschar; Deep dermal facial burn; Dermis preservation; Enzymatic debridement; Objective and subjective long term scar evaluation

Mesh:

Substances:

Year:  2017        PMID: 28363663     DOI: 10.1016/j.burns.2017.02.016

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  9 in total

1.  Does Platelet-Rich Fibrin Enhance Healing Of Burn Wounds? Our First Experiences And Main Pitfalls.

Authors:  A Schulz; J L Schiefer; P C Fuchs; C H Kanho; N Nourah; W Heitzmann
Journal:  Ann Burns Fire Disasters       Date:  2021-03-31

2.  Our Initial Experience In The Customized Treatment Of Donor Site And Burn Wounds With A New Nanofibrous Temporary Epidermal Layer.

Authors:  A Schulz; P C Fuchs; W Heitzmann; C H Kanho; J L Schiefer
Journal:  Ann Burns Fire Disasters       Date:  2021-03-31

3.  Bromelain-based enzymatic debridement of chronic wounds: A preliminary report.

Authors:  Yaron Shoham; Yuval Krieger; Eran Tamir; Eldad Silberstein; Alexander Bogdanov-Berezovsky; Josef Haik; Lior Rosenberg
Journal:  Int Wound J       Date:  2018-04-25       Impact factor: 3.315

4.  Limitations to the use of bromelain-based enzymatic debridement (NexoBrid®) for treating diabetic foot burns: a case series of disappointing results.

Authors:  Juan Enrique Berner; Dejan Keckes; Matthew Pywell; Baljit Dheansa
Journal:  Scars Burn Heal       Date:  2018-12-05

5.  Bromelain-based enzymatic debridement as a treatment of choice in high-risk patient with deep facial burns, a case report.

Authors:  Nikola Ferancikova; Peter Bukovcan; Nina Sarkozyova; Jana Dragunova; Valeria Cucorova; Jan Koller
Journal:  Int J Surg Case Rep       Date:  2020-05-11

6.  Preliminary Single-Center Experience of Bromelain-Based Eschar Removal in Children with Mixed Deep Dermal and Full Thickness Burns.

Authors:  Tomasz Korzeniowski; Ewelina Grywalska; Jerzy Strużyna; Magdalena Bugaj-Tobiasz; Agnieszka Surowiecka; Izabela Korona-Głowniak; Magdalena Staśkiewicz; Kamil Torres
Journal:  J Clin Med       Date:  2022-08-17       Impact factor: 4.964

7.  Bromelain-based enzymatic burn debridement: Spanish multidisciplinary consensus.

Authors:  Jordi Serracanta; Jacinto Baena; José R Martinez-Mendez; Manuel Sanchez-Sanchez; Eugenia Lopez-Suso; Rita Galeiras; Maria Dolores Perez-Del-Caz; Carmen Vivo-Benlloch; Enrique Monclus-Fuertes; Jacobo Casalduero-Viu; Patricia Martin-Playa; Marta Ugalde-Gutierrez; Purificacion Gacto-Sanchez; Maria Dolores Rincon-Ferrari; Jose Maria Piqueras-Perez; Ana Martin-Luengo
Journal:  Eur J Plast Surg       Date:  2022-09-29

8.  A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by Bromelain-Based Enzymatic Debridement (Nexobrid®) in Burns Following the 2020 Updated European Consensus Guidelines.

Authors:  Tomasz Korzeniowski; Jerzy Strużyna; Anna M Chrapusta; Andrzej Krajewski; Marek Kucharzewski; Krzysztof Piorun; Jakub Nowakowski; Agnieszka Surowiecka; Magdalena Kozicka; Kamil Torres
Journal:  Med Sci Monit       Date:  2022-01-22

9.  Enzymatic Debridement for Burn Wound Care: Interrater Reliability and Impact of Experience in Post-intervention Therapy Decision.

Authors:  Laura C Siegwart; Arne H Böcker; Yannick F Diehm; Dimitra Kotsougiani-Fischer; Stella Erdmann; Benjamin Ziegler; Ulrich Kneser; Christoph Hirche; Sebastian Fischer
Journal:  J Burn Care Res       Date:  2021-09-30       Impact factor: 1.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.